High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans
An HPLC analysis was developed for the measurement of rufloxacin and two of its possible metabolites N-desmethylrufloxacin and rufloxacinsulfoxide. Humans are unable to form these two metabolites, while no other metabolites could be detected in the HPLC chromatogram. The half-life of elimination of rufloxacin in two human subjects was 27 and 38 h respectively, while a constant percentage of 25–26% of the dose is excreted unchanged in the urine.
KeywordsHPLC analysis rufloxacin N-desmethylrufloxacin rufloxacinsulfoxide renal excretion rate pharmacokinetics humans
Unable to display preview. Download preview PDF.
- 2.Ravizzola G., Pinsi G., Pirali F., Colombrita D., Turano A. (1989): Rufloxacin (MF 934): in vitro and in vivo antibacterial activity. Drug Exptl. Clin. Res., 15, 11–15.Google Scholar
- 3.Ravizzola G., Pinsi G., Pirali F., Colombrita D., Turano A. (1991): Rufloxacin (MF-934); pharmacokinetic properties and “in vitro”s activity. Eur. J. Clin. Microbiol. Infect Dis., In press.Google Scholar
- 7.Vree T.B., van den Biggelaar-Martea M., Peeters A., Imbimbo B.P. (1992): High-performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in urine of Rhesus monkeyMacaca mulatto. J. Chromatogr. Biomed. Appl., 573, 168–172.CrossRefGoogle Scholar
- 9.Janssen T.J., Guelen P.J.M., Vree T.B. (1987): Pharmacokinetics of fleroxacin (Ro 23-6240) after a single oral dose to healthy volunteers. In: Berkada B. Kümmerle H.P. Eds. Progress in Chemotherapy, antimicrobial section, vol. I, pp. 206–208.Google Scholar